sah1’s details
| symbol | subject | date & time | rating |
|
|
PLI was in New York and Boston over the last couple of days. According to Fred, the feedback from one of the funds can be summed up as follows: 'Our sales guys really liked the company…..think it could be a monster if you guys keep ex... |
5/2/2013 12:23:36 PM |
4 |
|
|
Yes. From what I was told, the structural changes were begun in January. Thus the refurbishment must be at a stage where the PPPS process and equipment can now be installed. This set -up will be exactly the same as CNBG's plant in China so th... |
4/30/2013 3:37:29 PM |
4 |
|
|
This announcement is long overdue and should be well received by the markets. Sarorius' commitment to provide the equipment and consumables for the next 3 years reduces the out of pocket costs for PLI for the refurbishment of the Laval plant ... |
4/30/2013 6:54:03 AM |
4 |
|
|
Here it is in full PROMETIC AND SARTORIUS STEDIM BIOTECH (“SSB”) JOIN FORCES TO PROMOTE NOVEL TURNKEY SOLUTION FOR PRODUCING PLASMA-DERIVED THERAPEUTICSProMetic BioProduction's plasma purification facility to become the technolo... |
4/30/2013 6:14:43 AM |
|
|
|
Check out the two presentations below. It is clear that with Albupure and other contaminant removal capacity, PLI's technology and products are integral to Novozyme's award winning albumin based drug delivery platforms. Already two pharma... |
4/27/2013 3:32:50 AM |
5 |
|
|
Thank you Holder21. Much appreciated. |
4/26/2013 1:33:12 PM |
|
|
|
Explain why this question is of interest? |
4/25/2013 5:45:25 PM |
|
|
|
Haiti, I don't want to rain on your parade but why don't you check if Abraxane was introduced before Alpupure came on the market.. If it did then a move to albupure would mean that Celgene would have to go back to the FDA to get approval ... |
4/25/2013 4:04:58 PM |
|
|
|
Haiti, Celgene bought ' intellectual property rights for specific commercial application of PLI's Protein Technologies within restricted fields of use' to quote the press release. My guess at the time was that the rights related to p... |
4/24/2013 1:20:10 PM |
|
|
|
I couldn't agree more, mtnbkr. The main risk facing PLI at this juncture is 'execution risk' and frankly that is relatively small. In the protein division, revenue capacity of PLI's two manufacturing plants ($150M - Laval for PPPS... |
4/24/2013 5:23:50 AM |
4 |
|
No additional content to display.
Stockhouse.com: Taking
it to the street
